Patents by Inventor Arvind Natarajan

Arvind Natarajan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230293685
    Abstract: The present invention provides methods for preselecting TILs based on PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3 and/or TIGIT expression, as well as methods for expanding those preselected PD-1, CD39, CD38, CD103, CD101, LAG3, TIM3 and/or TIGIT positive TILs in order to produce therapeutic populations of TILs with enhanced tumor-specific killing capacity (e.g., enhanced cytotoxicity).
    Type: Application
    Filed: May 4, 2021
    Publication date: September 21, 2023
    Inventors: Michelle Simpson-Abelson, Arvind Natarajan
  • Publication number: 20230039976
    Abstract: The present invention provides methods for preselecting TILs based on PD-1 expression, as well as methods for expanding those preselected PD-1 positive TILs in order to produce therapeutic populations of TILs with enhanced tumor-specific killing capacity (e.g., enhanced cytotoxicity).
    Type: Application
    Filed: November 4, 2019
    Publication date: February 9, 2023
    Inventors: Michelle Simpson-Abelson, Arvind Natarajan, Cecile Chartier-Courtaud, Matt Paulson
  • Publication number: 20220118012
    Abstract: The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.
    Type: Application
    Filed: September 3, 2019
    Publication date: April 21, 2022
    Inventors: Maria Fardis, Arvind Natarajan
  • Publication number: 20220088069
    Abstract: The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.
    Type: Application
    Filed: May 14, 2020
    Publication date: March 24, 2022
    Inventors: Maria Fardis, Arvind Natarajan
  • Patent number: 6555360
    Abstract: For direct and on-line study of the physiological states of cell cultures, a robust flow injection system has been designed and interfaced with flow cytometry (FI-FCM). The core of the flow injection system includes a microchamber designed for sample processing. The design of the microchamber allows not only an accurate on-line dilution but also on-line cell fixation, staining, and washing. The flow injection part of the system was tested by monitoring the optical density of a growing E.coli culture on-line using a spectrophotometer. The entire growth curve, from lag phase to stationary phase, was obtained with frequent sampling. The system is thus particularly useful since it operates automatically without direct operator supervision for extended time periods.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: April 29, 2003
    Inventors: Friedrich Srienc, Rui Zhao, Arvind Natarajan